Tetracycline prevents Aβ oligomer toxicity through an atypical supramolecular interaction

Cristina Airoldi1, Laura Colombo, Claudia Manzoni

  • 1Department of Biotechnology and Biosciences, University of Milano-Bicocca, P.zza della Scienza 2, 20126, Milan, Italy.

Insights

The antibiotic tetracycline inhibits amyloid-beta aggregation and toxicity by interacting with oligomers, not monomers. This supramolecular interaction improves peptide solubility and prevents amyloid cascade progression.

Area of Science:

  • Biochemistry
  • Neuroscience
  • Pharmacology

Background:

  • Amyloidogenic proteins, such as amyloid-beta (Aβ), are implicated in neurodegenerative diseases.
  • Tetracycline has demonstrated anti-amyloidogenic properties in various models.
  • The precise mechanism by which tetracycline affects Aβ aggregation remains incompletely understood.

Purpose of the Study:

  • To elucidate the molecular and supramolecular mechanisms of tetracycline's interaction with Aβ1-40 and Aβ1-42.
  • To investigate how tetracycline modulates Aβ aggregation and toxicity.

Main Methods:

  • Nuclear Magnetic Resonance (NMR) spectroscopy, including Saturation Transfer Difference (STD) and NOESY experiments.
  • Fourier-Transform Infrared (FTIR) spectroscopy.
  • Dynamic Light Scattering (DLS) and Atomic Force Microscopy (AFM).

Main Results:

  • Tetracycline dose-dependently reduced the toxicity of Aβ1-42 oligomers to N2a cells.
  • NMR studies indicated tetracycline interacts with Aβ oligomers but not monomers, suggesting a supramolecular interaction without a specific binding site.
  • DLS and AFM revealed that co-dissolution of Aβ peptides and tetracycline promotes new aggregate formation, enhancing Aβ solubility and inhibiting the amyloid cascade.
  • Competitive NMR binding experiments demonstrated tetracycline competes with thioflavin T (ThT) for Aβ binding.

Conclusions:

  • Tetracycline exhibits anti-amyloidogenic activity through a novel mechanism involving supramolecular interactions with Aβ oligomers.
  • This interaction enhances Aβ peptide solubility and prevents amyloid cascade progression.
  • The findings provide insights into tetracycline's therapeutic potential for amyloid-related diseases.

Related Concept Videos

Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...